MYX logo

Mayne Pharma Group Stock Price

Symbol: ASX:MYXMarket Cap: AU$405.4mCategory: Pharmaceuticals & Biotech

MYX Share Price Performance

AU$4.99
1.11 (28.61%)
AU$4.99
1.11 (28.61%)
Price AU$4.99

MYX Community Narratives

There are no narratives available yet.

Recent MYX News & Updates

No updates

Mayne Pharma Group Limited Key Details

AU$413.5m

Revenue

AU$169.7m

Cost of Revenue

AU$243.9m

Gross Profit

AU$361.9m

Other Expenses

-AU$118.0m

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Aug 29, 2025
Earnings per share (EPS)
-1.45
Gross Margin
58.97%
Net Profit Margin
-28.54%
Debt/Equity Ratio
7.5%

Mayne Pharma Group Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About MYX

Founded
2005
Employees
n/a
CEO
Shawn O’Brien
WebsiteView website
www.maynepharma.com

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Australian Market Performance

  • 7 Days: 1.2%
  • 3 Months: 7.7%
  • 1 Year: 15.0%
  • Year to Date: 7.3%
The market is up 1.2% over the last week, with the Materials sector leading the way, up 4.0%. In the last year, the market has climbed 15%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading